Duobrii treatment for psoriasis patients on biologics
Open Label Study Evaluating DUOBRII in Psoriasis Patients Being Treated With Biologic Agents.
PHASE4 · Psoriasis Treatment Center of Central New Jersey · NCT04119102
This study is testing if adding Duobrii to the treatment of psoriasis patients already on biologics can help improve their skin condition.
Quick facts
| Phase | PHASE4 |
|---|---|
| Study type | Interventional |
| Enrollment | 25 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Psoriasis Treatment Center of Central New Jersey (other) |
| Locations | 1 site (East Windsor, New Jersey) |
| Trial ID | NCT04119102 on ClinicalTrials.gov |
What this trial studies
This pilot study evaluates the effectiveness of Duobrii in patients with chronic plaque psoriasis who have a body surface area involvement of 2%-10% and have been on biologic therapy for at least 24 weeks. Conducted at a single center, the study will involve 25 subjects over a 12-week treatment period. The aim is to assess the potential benefits of adding Duobrii to their existing treatment regimen.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with chronic plaque psoriasis affecting 2%-10% of their body surface area who have been on biologic therapy for at least 24 weeks.
Not a fit: Patients with psoriasis affecting less than 2% or more than 10% of their body surface area or those not currently receiving biologic therapy will not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could enhance the management of psoriasis in patients already receiving biologic therapy.
How similar studies have performed: While this approach is relatively novel, similar studies have shown promise in enhancing treatment outcomes for psoriasis patients on biologics.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male or female adult ≥ 18 years of age; 2. Diagnosis of chronic plaque-type 3. Psoriasis affecting 2%-10% BSA 4. Patient is being treated with biologic therapy for a minimum of 24 weeks 5. Able and willing to give written informed consent prior to performance of any study-related procedures Exclusion Criteria: 1. Psoriasis affecting ˂2% or \>10% BSA 2. Patient not receiving a biologic agent, or receiving biologic agent \<24weeks 3. Received treatment with any topical antipsoriatic drug product within 14 days prior to the Baseline visit. 4. Has previously used DUOBRII
Where this trial is running
East Windsor, New Jersey
- Psoriasis Treatment Center of Central New Jersey — East Windsor, New Jersey, United States (RECRUITING)
Study contacts
- Study coordinator: Jerry Bagel, MD
- Email: dreamacres1@aol.com
- Phone: 6094434500
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Psoriasis